IL273543B1 - New treatment for SMA - Google Patents

New treatment for SMA

Info

Publication number
IL273543B1
IL273543B1 IL273543A IL27354320A IL273543B1 IL 273543 B1 IL273543 B1 IL 273543B1 IL 273543 A IL273543 A IL 273543A IL 27354320 A IL27354320 A IL 27354320A IL 273543 B1 IL273543 B1 IL 273543B1
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
dimethylimidazo
diazaspiro
octan
pyridazin
Prior art date
Application number
IL273543A
Other languages
Hebrew (he)
Other versions
IL273543A (en
IL273543B2 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60019743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL273543(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL273543A publication Critical patent/IL273543A/en
Publication of IL273543B1 publication Critical patent/IL273543B1/en
Publication of IL273543B2 publication Critical patent/IL273543B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)

Description

WO 2019/068604 -1- PCT/EP2018/076577 New treatment of SMA The invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2- b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
Spinal muscular atrophy (SMA), in its broadest sense, describes a collection of inherited and acquired central nervous system (CNS) diseases characterized by progressive motor neuron loss in the spinal cord and brainstem causing muscle weakness and muscle atrophy. SMA is characterized by a degeneration of the alpha motor neurons from the anterior horn of the spinal cord leading to muscular atrophy and resulting in paralysis. This alpha motor neuron degeneration thus substantially compromises the vital prognosis of patients. In healthy subjects, these neurons transmit messages from the brain to the muscles, leading to the contraction of the latter. In the absence of such a stimulation, the muscles atrophy. Subsequently, in addition to a generalized weakness and atrophy of the muscles, and more particularly of those of the trunk, upper arms and thighs, these disorders can be accompanied by serious respiratory problems.

Claims (18)

273543/- 72 - Claims
1. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA at 5 mg for patient with a body weight of more than or equal to 20kg.
2. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to claim 1, in patient in need thereof, wherein the patient is a human.
3. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to claim 1 or 2, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one is orally administered.
4. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 3, wherein the patient is a human, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one is being administered orally at 5mg for patients with a body weight of more than or equal to 20kg.
5. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 4, wherein SMA is type II SMA.
6. 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6- yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of SMA according to any one of claims 1 to 5, wherein 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one is administered once a day.
7. A pharmaceutical composition for use in the treatment of SMA, at 5 mg of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2- a]pyrimidin-4-one for patients with a body weight of more than or equal to 20kg, being administered, in particular orally administered once a day, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof formulated as oral aqueous solution by dissolving 7-(4,7-diazaspiro[2.5]octan-7- yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof in a buffer system at pH of less than pH 4, in order to provide sufficiently high drug concentration, e.g. citric buffer system, malate buffer system, maleate buffer system, or tartrate buffer system. 273543/- 73 -
8. The pharmaceutical composition for use according to claim 7, wherein the buffer system is at pH 3.0 to 3.2.
9. The pharmaceutical composition for use according to claim 7, wherein the buffer system is tartrate buffer system.
10. The pharmaceutical composition for use according to any one of claims 7 to 9, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof as a dry powder or granulation for constitution of an oral solution.
11. The pharmaceutical composition for use according to any one of claims 7 to 10, wherein a buffer system can be incorporated into dry formulation by the selection of organic acid and salts thereof as fine powders, e.g. tribasic sodium citrate and citric acid, disodium malate and malic acid, potassium sodium tartrate and tartaric acid, or disodium tartrate and tartaric acid.
12. The pharmaceutical composition for use according to any one of claims 7 to 10, wherein the pharmaceutical composition comprises 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof, a diluent, such as sorbitol, isomalt, or mannitol, and combinations thereof, which ensure fast dissolution of the powder blend during constitution of the oral solution and optionally, filler can be added to be granulated by dry compaction in order to improve the flowability and to ensure robust uniformity.
13. The pharmaceutical composition for use according to any one of claims 7 to 12, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; and  tartaric acid.
14. The pharmaceutical composition for use according to any one of claims 7 to 13, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof;  tartaric acid; and 273543/- 74 -  mannitol or a mixture of mannitol and isomalt.
15. The pharmaceutical composition for use according to any one of claims 7 to 14, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof; and  mannitol or a mixture of mannitol and isomalt.
16. The pharmaceutical composition for use according to any one of claims 7 to 15, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof;  tartaric acid;  ascorbic acid; and  disodium edetate.
17. The pharmaceutical composition for use according to any one of claims 7 to 16, wherein the pharmaceutical composition comprises:  7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof;  tartaric acid;  mannitol or a mixture of mannitol and isomalt;  ascorbic acid; and  disodium edetate.
18. The pharmaceutical composition for use according to any one of claims 7 to 12, wherein the pharmaceutical composition comprises: 273543/- 75 -  1 to 10 %wt of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable salt thereof;  5 to 15 %wt of a buffer system, particularly a buffer system selected from citrate, malate, maleate or tartrate, more particularly malate or tartrate, most particularly tartrate; or alternatively the corresponding acid of a buffer system alone as acidifier, particularly tartaric acid;  40 to 70 %wt of a diluent, particularly mannitol or a mixture of mannitol and isomalt, more particularly mannitol;  1 to 4 %wt of an antioxidant, particularly ascorbic acid;  0.5 to 2 %wt of a stabilizer, particularly disodium edetate;  0.5 to 2 %w of a lubricant, particularly PEG6000;  0 to 3 %wt of a sweetener, particularly sucralose or sodium saccharin, most particularly sucralose; and  0 to 20 %wt of a flavor, particularly strawberry flavor or vanilla flavor; wherein the total amount of ingredients does not exceed 100 %wt.
IL273543A 2017-10-03 2018-10-01 New treatment of sma IL273543B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17194520 2017-10-03
PCT/EP2018/076577 WO2019068604A1 (en) 2017-10-03 2018-10-01 New treatment of sma

Publications (3)

Publication Number Publication Date
IL273543A IL273543A (en) 2020-05-31
IL273543B1 true IL273543B1 (en) 2025-12-01
IL273543B2 IL273543B2 (en) 2026-04-01

Family

ID=60019743

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273543A IL273543B2 (en) 2017-10-03 2018-10-01 New treatment of sma
IL323792A IL323792A (en) 2017-10-03 2018-10-01 New treatment for SMA

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323792A IL323792A (en) 2017-10-03 2018-10-01 New treatment for SMA

Country Status (12)

Country Link
US (2) US11534444B2 (en)
EP (2) EP3691647B1 (en)
JP (3) JP7423515B2 (en)
KR (1) KR102761837B1 (en)
CN (2) CN111182900A (en)
AU (2) AU2018344402B2 (en)
CA (1) CA3078137A1 (en)
ES (1) ES3072590T3 (en)
IL (2) IL273543B2 (en)
MX (2) MX2020003416A (en)
TW (1) TWI870340B (en)
WO (1) WO2019068604A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3072590T3 (en) * 2017-10-03 2026-07-02 Hoffmann La Roche New treatment of sma
WO2020249577A1 (en) * 2019-06-12 2020-12-17 F. Hoffmann-La Roche Ag New treatment of sma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080967A1 (en) * 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
WO2017081111A1 (en) * 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compounds for treating amyotrophic lateral sclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
AU2015261046C1 (en) 2014-05-15 2019-07-25 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
MX375925B (en) * 2014-06-25 2025-03-07 Hoffmann La Roche IMIDAZO[1,2-A]PYRAZIN-1-YL-BENZAMIDE COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
ES3072590T3 (en) * 2017-10-03 2026-07-02 Hoffmann La Roche New treatment of sma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080967A1 (en) * 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
WO2017081111A1 (en) * 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compounds for treating amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
EP4755451A3 (en) 2026-08-19
US11534444B2 (en) 2022-12-27
KR20200065025A (en) 2020-06-08
JP2020536090A (en) 2020-12-10
JP2024041949A (en) 2024-03-27
EP3691647C0 (en) 2026-05-27
AU2018344402B2 (en) 2024-08-29
EP3691647A1 (en) 2020-08-12
IL273543A (en) 2020-05-31
EP4755451A2 (en) 2026-06-10
JP7423515B2 (en) 2024-01-29
EP3691647B1 (en) 2026-05-27
MX2020003416A (en) 2020-07-20
US20200375993A1 (en) 2020-12-03
IL323792A (en) 2025-12-01
TWI870340B (en) 2025-01-21
AU2018344402A1 (en) 2020-04-09
WO2019068604A1 (en) 2019-04-11
JP2024102152A (en) 2024-07-30
IL273543B2 (en) 2026-04-01
MX2023004924A (en) 2023-05-17
TW201924684A (en) 2019-07-01
ES3072590T3 (en) 2026-07-02
AU2024266812A1 (en) 2024-12-12
KR102761837B1 (en) 2025-02-05
CN117919251A (en) 2024-04-26
CA3078137A1 (en) 2019-04-11
US12350273B2 (en) 2025-07-08
CN111182900A (en) 2020-05-19
US20230338382A1 (en) 2023-10-26
JP7481593B2 (en) 2024-05-10

Similar Documents

Publication Publication Date Title
EP3003384B1 (en) Oral solution comprising atomoxetine hydrochloride
ES2726524T3 (en) Methotrexate composition
JPH0380127B2 (en)
EP2422787A1 (en) Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
CZ284928B6 (en) The use of riluzol or pharmaceutically acceptable salts thereof for preparing medicaments
CN102802418A (en) Compositions and methods for treating amyotrophic lateral sclerosis
US20250352468A1 (en) Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
TWI549678B (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
ES2822562T3 (en) Intranasal compositions for the treatment of neurological and degenerative diseases and disorders
EP2563340A2 (en) Water soluble pharmaceutical composition
JP2022536669A5 (en)
IL323792A (en) New treatment for SMA
JP7745086B2 (en) Pharmaceutical compositions and applications of ARNi and calcium ion antagonists
CA3180526A1 (en) Formulations
WO2010110428A1 (en) Prophylactic and/or therapeutic agent for pruritus
KR20050058468A (en) Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
CN1372468A (en) Oral preparations of etidronate disodium
TWI893157B (en) Use of a compound having a morphinan skeleton or a pharmacologically acceptable acid addition salt thereof
EP3678498B1 (en) Composition for calcium supplementation
JP2001526217A (en) Novel use of local anesthetics for vascular headache
KR20190127885A (en) Formulations for myopia prevention, myopia treatment, and / or prevention of myopia progression, comprising tiotropium as active ingredient
JP2006502234A (en) Treatment of dyskinesia
EP3678497B1 (en) Composition for calcium supplementation
AU761978B2 (en) Use of 2-amino-6- trifluoromehthoxy- benzothiazole for preventing or treating cerebellum dysfunction
HK1205951A1 (en) Use of 7-t-butoxyiminomethylcamptothecin for the prepartion of a medicament for the treatment of uterine neoplasms